Details of the Drug Reposition

General Information of This Drug (ID: DMRLZA1)

Drug Name
ZW25   DMRLZA1
Synonyms Zanidatamab
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Oesophagogastric junction cancer DISSLH1X 2B71.Z Phase 2 [1]
Biliary tract cancer DISBNYQL 2C17 Phase 2 [2]
Breast cancer DIS7DPX1 2C60-2C65 Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ovarian cancer DISZJHAP 2C73 Phase 1 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04224272) A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04466891) A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)